CN102861114A - Kiwi fruit extract and extraction method and application thereof - Google Patents
Kiwi fruit extract and extraction method and application thereof Download PDFInfo
- Publication number
- CN102861114A CN102861114A CN2012103853628A CN201210385362A CN102861114A CN 102861114 A CN102861114 A CN 102861114A CN 2012103853628 A CN2012103853628 A CN 2012103853628A CN 201210385362 A CN201210385362 A CN 201210385362A CN 102861114 A CN102861114 A CN 102861114A
- Authority
- CN
- China
- Prior art keywords
- fructus actinidiae
- actinidiae chinensis
- extract
- extraction
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a kiwi fruit extract and an extraction method and an application thereof. The extraction method of the kiwi fruit extract includes that fresh kiwi fruits with skins are cut up, the cut fresh kiwi fruits are heated by methanol and subjected to reflux extraction for two times, the first time of the reflux extraction is performed for 1.5 hours to 2.5 hours, the second time of the reflux extraction is performed for 0.5 hour to 1.5 hours, the twice extracting solutions are combined, filtered and concentrated to obtain a kiwi fruit methanol total extract, the kiwi fruit methanol total extract is subjected to extraction by petroleum ether, ethyl acetate and n-butyl alcohol sequentially, and after reduced pressure suction filtration and concentration, a kiwi fruit petroleum ether extracting part, an ethyl acetate extracting part and an n-butyl alcohol extracting part are respectively obtained. According to internal experiment, acarbose serves as positive control, the therapeutic effect of the kiwi fruit petroleum ether, the ethyl acetate and the n-butyl alcohol extracting parts on a diabetic mouse which is induced by alloxan is observed, and the experimental result shows that a certain therapeutic effect of kiwi fruit ACPE, ACEA and ACBU on the diabetic mouse which is induced by the alloxan is achieved.
Description
Technical field
The present invention relates to a kind of Fructus actinidiae chinensis extract, in addition, also relate to a kind of extracting method of this Fructus actinidiae chinensis extract, with and in the application of preparation aspect the hypoglycemic drug; Relate in particular to a kind of Fructus actinidiae chinensis extract part and preparing alpha-glucosidase inhibitor medicine in the application aspect the blood sugar lowering.
Background technology
Fructus actinidiae chinensis is the fruit of Actinidiaceae plant Fructus actinidiae chinensis (Actinidia chinensis Planch), has another name called Fructus actinidiae chinensis, Radix actinidiae argutae, carambola etc., is born in mountain region woodland or the shrubbery, often is wrapped on his thing.Be distributed in Central-South and the ground such as Shaanxi, Jiangsu, Anhui, Zhejiang, Jiangxi, Fujian, Sichuan, Guizhou, Yunnan, sour in the mouth, sweet, cold in nature.Return stomach.Liver, kidney channel.Have analgesic, quench the thirst stomach invigorating, treating stranguria function.Cure mainly dysphoria with smothery sensation, quench one's thirst, lung-heat dry cough, dyspepsia, jaundice due to damp-heat, stranguria caused by urinary stone, hemorrhoid.By consulting literatures is found, be rich in volatile ingredient in the kiwi fruit, multivitamin, organic acid, flavone, actinidine, the number of chemical compositions such as polysaccharide and multiple human body essential amino acid and trace element, pharmacological research shows, it has blood fat reducing, anti peroxidation of lipid, the antagonism cytotoxicity, mutation, protect the liver, anti-cancer, improve the pharmacologically active of the aspects such as immunity, possessed the edible medicinal function of holding concurrently, but have no report about Fructus actinidiae chinensis in the research aspect the alpha-glucosidase inhibitor, need further further investigation, develop its practical application aspect Remedies for diabetes.
Diabetes (diabetes) are to act on that body causes hypoinsulinism, insulin resistant etc. and a series of metabolism disorder syndromes such as the sugar that causes, protein, fat, power and water Xie Zhi by various virulence factors such as inherited genetic factors, immunologic function disorder, infected by microbes and toxin thereof, free radical toxin, Nervous and Mental Factors, comprise take insulin absolute lack as main type Ⅰ diabetes mellitus and take insulin relatively lack and insulin resistant as the diabetes of master's type Ⅱdiabetes mellitus, gestational diabetes and other specific types.Clinically take hyperglycemia as main feature, the performances such as polyuria, polydipsia, polyphagia can appear in model case, become thin, i.e. " three-many-one-little " symptom, diabetes (blood glucose) are in case control and badly can cause complication, cause the depleted pathological changes at the positions such as kidney, eye, foot, and can't cure.At present, diabetes have worldwide become the third-largest chronic disease of serious harm human health after cardiovascular and cerebrovascular disease, tumor.
Diabetes are one of universally acknowledged pertinacious diseases, and people were difficult to cure after getting diabetes, usually needed Long-term taking medicine; The duration of disease can reach decades.The main harm of diabetes is not diabetes itself, but the various chronic complicating diseases that in the diabetes evolution, occur.Endothelium inflammatory reaction and vascular smooth muscle cell proliferation etc. caused the diabetes and cardiovascular diseases such as atherosclerosis and coronary heart disease after the macroangiopathy that diabetes cause can cause arteriosclerosis, systolic and diastolic function obstacle and increase the weight of blood vessel injury; Diabetic microvascular complication then can cause hypertension, diabetic nephropathy and diabetic renal papillary necrosis.Although the modern medicine technology can have been controlled the blood glucose of Most patients effectively, but still can't effectively prevent and treat the chronic complicating diseases that diabetes cause.Because the frequently-occurring and seriousness of diabetic complication, diabetes have become the fifth-largest fatal disease in the world.
Along with China recent years economy and social development levels improve rapidly, caused the variation of people life style and dietary structure, China's diabetes prevalence also is obvious ascendant trend.China's diabetes prevalence from 1980 0.67% rise to 2004 5.5%, 9 times have been increased, in world health in 2012 statistics first having included in wherein about the data of hyperglycemic patients, although the average prevalence in the whole world is about 10%, but in some Pacific Islands countries, suffers from this disease up to 1/3rd population.Untimely treatment, diabetes can cause cardiovascular disease, blind and renal failure.At present, the diabetics of China is next in number only to India, is diabetes the second big country in the world.More alarmingly be, defend microstructure Prediction according to the world, during by 203 years, the diabetics number of China might double, and therefore, prevention and treatment diabetes have become China and even global health care problem.
Recent study is found, postprandial hyperglycemia often occurs first in the sick process of diabetes, then develops into diabetes, and namely the former is the latter's in advance sign.For diabetics, II type patient particularly, postprandial hyperglycemia to the harm of body considerably beyond hyperglycemia, postprandial hyperglycemia not only very easily brings out various complication, also can greatly improve the mortality rate of diabetes, so reducing post-prandial glycemia is prevent diabetes, one of important measures of complication and reduction mortality rate that is to say that the control post-prandial glycemia is the control hyperglycemia, prevents and treats the Important Action of diabetes.In diabetic, approximately the diabetic more than 90% belongs to type Ⅱdiabetes mellitus, mainly pass through at present oral antidiabetic drug, the control fasting glucose reaches therapeutic purposes, medicine mainly concentrates on Drugs Promoting Insulin Secretion such as sulphanylureas (glibenclamide, glipizide) for a long time, is mainly used in reducing the blood glucose of the diabetics that normal person or insulin function not yet completely lose; Strengthen medicine such as the biguanides (phenformin, metformin) of periphery glucose utilization, to no matter having or not the diabetics of islet function that blood sugar reducing function is all arranged, this two classes medicine also can bring larger side effect when reducing fasting glucose, and not obvious to the effect that reduces post-prandial glycemia.
Alpha-glucosidase inhibitor is a class reaches the treatment diabetes to delay the intestinal carbohydrate absorption orally-taken blood sugar reducing medicine.Replace gradually at present sulphanylureas and biguanides, be widely used in clinically, this type of medicine has acarbose, voglibose and miglitol.Its mechanism of action is: competitive inhibition is positioned at the various alpha-glucosidases of small intestinal, and the speed that makes starch based be decomposed into glucose slows down, thereby slows down the absorption of glucose in the intestinal, reduces postprandial hyperglycemia.Alpha-glucosidase inhibitor can effectively be controlled the rising of post-prandial glycemia, the generation of prevent diabetes, the appearance of complication, reduce mortality rate, in addition, do not stimulate β emiocytosis insulin, but can reduce after the meal insulin level, explanation can increase the sensitivity of insulin.
Summary of the invention
The object of the present invention is to provide a kind of Fructus actinidiae chinensis extract.
The present invention also aims to provide a kind of extracting method of this Fructus actinidiae chinensis extract.
Further, the object of the present invention is to provide the application of a kind of Fructus actinidiae chinensis extract aspect blood sugar lowering.
Further, the present invention also aims to provide the application of a kind of Fructus actinidiae chinensis extract part aspect the preparation hypoglycemic drug, the application that especially prepares the alpha-glucosidase inhibitor medicine aspect.
To achieve these goals, technical scheme of the present invention has adopted a kind of Fructus actinidiae chinensis extract, is extracted by following methods to obtain: get fresh belt leather Fructus actinidiae chinensis, with its chopping, with methanol heating and refluxing extraction twice, be followed successively by 1.5-2.5h, 0.5-1.5h; Extracted twice liquid is merged, filters, concentrate to get Fructus actinidiae chinensis methanol total extract; Fructus actinidiae chinensis methanol total extract is used petroleum ether, ethyl acetate, n-butanol extraction successively, decompress filter, concentrated Fructus actinidiae chinensis Petroleum ether extraction position, ethyl acetate extraction position and the n-butanol extraction position of obtaining respectively.
Described extract be Fructus actinidiae chinensis ligroin extraction, ethyl acetate extraction or n-butanol extract in a kind of or its combination in any.
Technical program of the present invention also lies in adopting a kind of extracting method of Fructus actinidiae chinensis extract, the method that may further comprise the steps: get fresh belt leather Fructus actinidiae chinensis, with its chopping, be 60-80 ℃ of reflux, extract, twice with the methanol heating-up temperature, be followed successively by 1.5-2.5h, 0.5-1.5h; Extracted twice liquid is merged, filters, concentrate to get Fructus actinidiae chinensis methanol total extract; Fructus actinidiae chinensis methanol total extract is used petroleum ether, ethyl acetate, n-butanol extraction successively, decompress filter, concentrated Fructus actinidiae chinensis Petroleum ether extraction position, ethyl acetate extraction position and the n-butanol extraction position of obtaining respectively.
In addition, technical scheme of the present invention has also adopted the application of a kind of Fructus actinidiae chinensis extract aspect blood sugar lowering; Especially the application aspect the preparation hypoglycemic drug.
Simultaneously, technical scheme of the present invention has also adopted the application of a kind of Fructus actinidiae chinensis extract aspect the preparation alpha-glucosidase inhibitor medicine and alpha-glucosidase inhibitor medicine application aspect the blood sugar lowering in the glycosuria sick body of Fructus actinidiae chinensis extract preparation.
Fructus actinidiae chinensis extract part of the present invention comes from petroleum ether, ethyl acetate and the n-butanol extraction position of Fructus actinidiae chinensis.Fructus actinidiae chinensis extract part of the present invention derives from the fruit of Actinidiaceae actinidia Fructus actinidiae chinensis, is born in mountain region woodland or the shrubbery, often is wrapped on his thing.Be distributed in Central-South and the ground such as Shaanxi, Jiangsu, Anhui, Zhejiang, Jiangxi, Fujian, Sichuan, Guizhou, Yunnan.Suppress the activity experiment screening through external alpha-glucosidase, the positive contrast medicine of acarbose (Acarbose), observe Fructus actinidiae chinensis Petroleum ether extraction position (ACPE), ethyl acetate extraction position (ACEA) and n-butanol extraction position (ACBU) three kinds of extract parts are to the inhibitory action of alpha-glucosidase, experimental result shows that each extract part of Fructus actinidiae chinensis all has certain inhibitory action to alpha-glucosidase, and in the certain mass concentration range, be dose dependent, after suppression ratio acquires a certain degree, increasing its mass concentration, suppressing activity is not increasing.Wherein when identical primary dcreening operation mass concentration (1500 μ g/mL), the suppression ratio of each extract part is all greater than 96%, near 100%, all greater than positive control drug (57.26%); Half-inhibition concentration IC from each extract part
50Value is analyzed: ACPE is to the highest (IC of inhibition activity of alpha-glucosidase
50=57.8 μ g/mL), be ACEA (IC secondly
50=84.7 μ g/mL) and ACBU (IC
50=124.7 μ g/mL), its activity is all far above positive control (IC
50=1103.01 μ g/mL).
Experiment is with the positive contrast of acarbose (Acarbose) in body, observe the therapeutical effect of the diabetic mice that Fructus actinidiae chinensis petroleum ether, ethyl acetate and three kinds of extract parts of n-butyl alcohol induce alloxan, experimental result shows, the diabetic mice that Fructus actinidiae chinensis ACPE, ACEA and ACBU induce alloxan all has certain therapeutical effect, can be by promoting the synthetic of hepatic glycogen, reduce the approach such as decomposition of liver glycogen, reduce fasting glucose and the level of postprandial blood sugar of diabetes; The content of TCH and TG improves diabetic complication in the reduction serum, such as hyperlipidemia, corrects the lipid metabolic disorder of diabetic mice; By the content of MDA in the reduction serum, the increased SOD level, the anti-oxidation function of enhancing diabetic mice body, the protection body is avoided the further injury of free radical, and then reaches the effect for the treatment of diabetes.
Description of drawings
Fig. 1 is the different extracted parts mass concentration of the present invention suppresses activity influence to alpha-glucosidase curve chart.
The specific embodiment
Embodiment 1
The Fructus actinidiae chinensis extract of the present embodiment is extracted by following methods and obtains, get fresh belt leather Fructus actinidiae chinensis, with its chopping, with 70 ℃ of reflux, extract, twice of methanol heating, be followed successively by 2h, 1h, extracted twice liquid merges, filters, concentrate to get Fructus actinidiae chinensis methanol total extract, total extract is used petroleum ether, ethyl acetate, n-butanol extraction successively, decompress filter, concentrated Fructus actinidiae chinensis Petroleum ether extraction position, ethyl acetate extraction position and the n-butanol extraction position of obtaining.
The yield of different solvents Fructus actinidiae chinensis extract part sees Table 1.
Embodiment 2
The present embodiment is the external alpha-glucoside inhibiting activity test of Fructus actinidiae chinensis extract
Method: 96 Microdilution plate methods
Principle: alpha-D-glucose glycosides enzymatic hydrolysis 4-Nitrobenzol-α-D-pyranglucoside (PNP-G), produce nitrophenol (PNP, yellow substance, at the 405nm place absorption maximum is arranged), but thereby alpha-glucosidase inhibitor Inhibiting α-glucosidase and Binding Capacity reduce the burst size of PNP.Calculate the enzyme inhibition activity of extract part with the changes of contents of PNP in the certain hour internal reaction system.
Instrument: LRH-150 constant incubator (Shanghai one permanent Science and Technology Ltd.); DELTA 320 type pH meters (U.S. Mettler-Toledo company); Multiskan MK3 microplate reader (U.S. Thermo Electron company); Electronic balance (U.S. Mettler-Toledo company); Rotary Evaporators (German Heidolph company).
Reagent: alpha-glucosidase (α-glucosidase, EC 3.2.1.20) and 4-Nitrobenzol-α-D-pyranglucoside (4-N-trophenyl-α-D-glucopyranoside, PNPG, 026K1516) are all available from U.S. Sigma company; Acarbose (Acarbose, Lot 16869, German Serva company); Dimethyl sulfoxine (DMSO, analytical pure, Tianjin moral grace chemical reagent company limited); Phosphate buffer (pH 6.8).Detection method:
112 μ L kaliumphosphate buffers (pH 6.8), adding concentration is 0.2U/mL alpha-glucosidase 20 μ L, 8 μ L sample solutions, 37 ℃ of constant temperature 15min add 20 μ L2.5mmol/L PNPG, 37 ℃ of isothermal reaction 15min.Add again 80 μ L, concentration is the terminator Na of 0.2mol/L
2CO
3Solution is surveyed the OD value under the 405nm wavelength.Experiment is established 4 groups altogether: sample sets (sample+buffer+enzyme+substrate), sample matched group (sample+buffer), blank group (DMSO+ buffer+enzyme+substrate), blank group (DMSO+ buffer), every group 3 parallel, survey the OD value in the 405nm place, calculate suppression ratio by following computing formula, and obtain corresponding IC with Origin 6.0 softwares
50Value.
Utilize respectively the said determination method to measure the IC of three kinds of extract parts of Fructus actinidiae chinensis and positive control acarbose
50Value.
Experimental result is as shown in table 1.
It is active that the alpha-glucosidase of table 1 Fructus actinidiae chinensis suppresses
Table?1The?α-glucosidase?inhibitory?activity?of?Actinidia?chinensis?Planch
Annotate :-expression undetermined;
The positive contrast of acarbose.
(1) as can be seen from Table 1, under same primary dcreening operation concentration 1500 μ g/mL, 3 extract parts of Fructus actinidiae chinensis (ACPE, ACEA and ACBU) all have higher suppression ratio to alpha-glucosidase, near 100%, be followed successively by from big to small ACPE〉ACBU〉ACEA, and all be higher than the positive control acarbose.For further the research inhibition is active, on the basis of primary dcreening operation concentration, carry out successively double dilution, calculation of half inhibitory concentration IC
50The result shows, in 3 extracts, ACPE is to the highest (IC of inhibition activity of alpha-glucosidase
50=57.8 μ g/ml), be ACEA (IC secondly
50=84.7 μ g/ml) and ACBU (IC
50=124.7 μ g/ml), its activity is all far above positive control acarbose (IC
50=1103.01 μ g/ml).
(2) Fig. 1 shows, in the certain mass concentration range, the Fructus actinidiae chinensis extract part of different solvents all is dose dependent to the inhibition activity of alpha-glucosidase, wherein ACEA and ACBU are when final concentration is 375 μ g/mL, suppression ratio is greater than 90%, when ACPE is 187.5 μ g/mL at final concentration, suppression ratio has reached 96.4%, after this increase again the mass concentration of 3 kinds of extract parts, suppression ratio is almost constant, and under same mass concentration, the size order of suppression ratio is: ACPE〉ACEA〉ACBU, above explanation, the Fructus actinidiae chinensis extract part is inverse relation to the active polarity size with extracting with solvent of the inhibition of alpha-glucosidase.
Experimental result shows, each extract part of Fructus actinidiae chinensis all has stronger inhibitory action to alpha-glucosidase, wherein, suppress active best with Fructus actinidiae chinensis petroleum ether and ethyl acetate extract, illustrate and have preferably by the fat-soluble or middle polarity composition of Fructus actinidiae chinensis alpha-glucosidase suppresses active, be good alpha-glucosidase inhibitor, have the possibility for the preparation of hypoglycemic drug.
Embodiment 3
The present embodiment is the interior blood sugar lowering test of the glycosuria sick body of Fructus actinidiae chinensis extract part.
The laboratory animal material: kunming mice is male, body weight 22 ± 2g.
Key instrument: UV-2000 type ultraviolet-uisible spectrophotometer (Shanghai You Nike Instr Ltd.); Multiskan MK3 microplate reader (U.S. Thermo Electron company); LRH-150 constant incubator (Shanghai one permanent Science and Technology Ltd.); Electronic balance (U.S. Mettler-Toledo company); Rotary Evaporators (German Heidolph company); CS-H1 type blender (Beijing is won and encouraged positive scientific ﹠ technical corporation); The trace of each specification.
Main agents: glucose assays test kit (ShangHai RongSheng Biology Pharmacy Co., Ltd, 20110901); Triglyceride (TG) mensuration test kit (east, Zhejiang bowl diagnostic products company limited, Lot:2011090034); T-CHOL (TCH) mensuration test kit (east, Zhejiang bowl diagnostic products company limited, Lot:201100025); Liver/inose unit measures test kit (bio-engineering research institute, 20111205 are built up in Nanjing), malonaldehyde (MDA) test kit (bio-engineering research institute, 20111130 are built up in Nanjing); SOD test kit (surveying total) (bio-engineering research institute, 20111201 are built up in Nanjing); Acarbose (Hangzhou Sino-U.S. China becomes pharmaceutical Co. Ltd for Acarbose, Lot:110704); Alloxan (Allxan monohydrate, Lot:10150059, AlfaAesar); Dehydrated alcohol (AR, Tianjin Fu Yu Fine Chemical Co., Ltd); Concentrated sulphuric acid (AR, Kaifeng prismatic crystal chemical reagent company limited, 09080634); Glacial acetic acid (AR, Kaifeng chemical reagent head factory, 961005).
Experiment group: test minute Normal group, diabetic model group, administration group.
Experimental technique: after the mice of buying back adapted to 7d, random minute was in groups, 10 of blank groups, and another group is diabetes modeling group.Diabetes modeling group causes diabetes by the disposable tail vein injection alloxan of 80mg/kg after fasting be can't help water 12-16h hour.Behind the normal nursing 72h, water 12h is can't help in fasting, eye socket is got blood, survey fasting blood glucose level, according to the blood glucose homeostatic principle mice of blood sugar level more than 11.1mmol/L is divided into 11 groups, every group 10: the high, medium and low dosage group of ACPE, the high, medium and low dosage group of ACEA, the high, medium and low dosage group of ACBU, acarbose positive controls, diabetic model group, Normal group is organized as blank.Except model group and blank group, other groups are the corresponding medicine of gavage respectively, 1 time/d, successive administration 7d, the 2h eye socket is got blood and is surveyed level of postprandial blood sugar after the last administration, and in fasting on that night 12h, 8d wins eyeball and gets blood, separation of serum is positioned over refrigerator 0-3 ℃ preservation, for fasting glucose, TG, TCH, MDA and SOD after the mensuration administration.Put to death animal, get liver and weigh, be used for measuring liver glycogen content.
Experimental result is as follows:
Table 2 Fructus actinidiae chinensis the different extracted parts on the impact of blood glucose in diabetic mice (
N=10)
Table?2?Effect?of?the?different?extracts?of?Actinidia?chinensis?Planch?treatment?on?blood?glucose
Annotate: the positive contrast of acarbose;
Compare with the blank group:
△ △ △P＜0.001,
△ △P＜0.01,
△P＜0.05;
Compare with model group:
* *P＜0.001,
*P＜0.01,
*P＜0.05;
Compare with positive controls:
###P＜0.001,
##P＜0.01,
#P＜0.05;
Table 3 Fructus actinidiae chinensis the different extracted parts on the impact of diabetic mice liver glycogen (
N=10)
Table3?Effect?of?the?different?extracts?of?Actinidia?chinensis?Planch?treatment?on?hepaticglycogen?conten?in?live
Annotate: the positive contrast of acarbose;
Compare with the blank group:
△ △ △P＜0.001,
△ △P＜0.01,
△P＜0.05;
Compare with model group:
* *P＜0.001,
*P＜0.01,
*P＜0.05;
Compare with positive controls:
###P＜0.001,
##P＜0.01,
#P＜0.05
Table 4 Fructus actinidiae chinensis the different extracted parts on the impact of TCH and TG in the diabetic mice serum (
N=10)
Table?4?Effect?of?the?different?extracts?of?Actinidia?chinensis?Planch?treatment?on?TCH?and?TG?indiabetic?mice
Annotate: the positive contrast of acarbose;
Compare with the blank group:
△ △ △P＜0.001,
△ △P＜0.01,
△P＜0.05;
Compare with model group:
* *P＜0.001,
*P＜0.01,
*P＜0.05;
Compare with positive controls:
###P＜0.001,
##P＜0.01,
#P＜0.05;
Table 5 Fructus actinidiae chinensis the different extracted parts on the impact of diabetic mice serum MDA and SOD (
N=10)
Table?5Effect?of?the?different?extracts?of?Actinidia?chinensis?Planch?treatment?on?MDA?and?SODin?diabetic?mice
Compare with the blank group:
△ △ △P＜0.001,
△ △P＜0.01,
△P＜0.05;
Compare with model group:
* *P＜0.001,
*P＜0.01,
*P＜0.05;
Compare with positive controls:
###P＜0.001,
##P＜0.01,
#P＜0.05;
(1) as can be seen from Table 2, before the administration, compare with the blank group, diabetic groups (ACPE, ACEA, ACBU, positive controls and model group) fasting glucose all is utmost point significance rising (P＜0.001), illustrate that alloxan induces diabetic mice modeling success and there was no significant difference between each administration group.
Behind the drug treatment 7d, compare with the blank group, the model group post-prandial glycemia is utmost point significance and raises (P＜0.001), the visible diabetes post-prandial glycemia that can raise; Compare with model group, ACPE low dose group, high, the middle dosage group of ACEA and ACBU low dose group can reduce post-prandial glycemia (P＜0.01 by significance respectively, P＜0.05, P＜0.001, P＜0.001), other administration groups reduce the post-prandial glycemia there was no significant difference, but post-prandial glycemia all is lower than model group.
Compare with model group, dosage group and positive controls can reduce post-prandial glycemia (P＜0.01 by significance respectively among ACPE low dose group, ACEA high dose group, the ACBU, P＜0.001, P＜0.05, P＜0.05), other administration groups reduce fasting glucose there was no significant differences, but are higher than the model group except ACBU high dose group fasting glucose, and other administration group fasting glucose all are lower than model group; Compare with positive controls, the ACEA high dose group can significantly reduce post-prandial glycemia (P＜0.05).
Post-prandial glycemia and fasting glucose analysis-by-synthesis after the administration, ACPE, ACEA and ACBU all have certain hypoglycemic activity, wherein ACPE low dose group and ACEA high dose group blood sugar decreasing effect are best, it is better that dosage group and ACBU low dose group reduce the post-prandial glycemia effect among the ACEA, and it is better that the dosage group reduces the fasting glucose effect among the AUBC.
(2) as can be seen from Table 3, compare the reduction (P＜0.001) of model group Mouse Liver glycogen content utmost point significance with the blank group; Behind the drug treatment 7d, compare with model group, the content (P＜0.01) of the rising liver glycogen that the ACPE high dose group can significance, in and low dose group not statistically significant (P〉0.05); Three dosage groups of ACEA liver glycogen content that all can raise, and have significant difference (P＜0.05, P＜0.01, P＜0.05); The ACBU low dose group can significance rising liver glycogen content (P＜0.05), the Mouse Liver glycogen content though senior middle school's dosage group can raise does not have statistical significance (P〉0.05); Compare with positive controls, each administration group of ACPE, ACEA and ACBU does not have statistical significance (P＞0.05) to liver glycogen content influence there was no significant difference.As seen, ACPE, ACEA and ACBU can reduce the approach such as decomposition of liver glycogen by promoting the synthetic of hepatic glycogen, reduce the blood sugar level of diabetes.
(3) as can be seen from Table 4, compare the rising (P＜0.001) of model group mice TCH content utmost point significance with the blank group; Behind the drug treatment 7d, compare with model group, ACPE, ACEA, ACBU and positive controls be the content (P＜0.001) of the reduction TCH of energy utmost point significance all, and compare there was no significant difference with the blank group (P〉0.05); The high low dose group of ACPE and ACBU all can significance reduction TG content (P＜0.05, P＜0.001, P＜0.05, P＜0.05), the ACEA high dose group can reduce TG content (P＜0.01) by significance; With the positive group is compared, each administration group of ACPE, ACEA and ACBU is on the impact of TCH and TG content there are no significant difference (P〉0.05).As seen, ACPE, ACEA and ACBU all can improve diabetic complication-hyperlipidemia by the content of TCH and TG in the reduction serum, correct the lipid metabolic disorder of diabetic mice.
(4) as can be seen from Table 4, compare with the blank group, MDA content utmost point significance raises (P＜0.001) in the model group mice serum, and SOD level utmost point significance reduces (P＜0.001).Behind the drug treatment 7d, compare with model group, all can be the extremely significant increased SOD level (P＜0.001) of the high, medium and low dosage group of ACPE, ACEA and ACBU, ACPE senior middle school low dose group, ACEA high dose group, the high low dose group of ACBU be reduction MDA content (P＜0.001 of energy utmost point significance all, P＜0.001, P＜0.001), the reduction MDA content (P＜0.01) of dosage energy highly significant among the ACBU.Compare with positive control, the high, medium and low dosage group of ACPE presents reduction MDA content (P＜0.001, P＜0.05, P＜0.01) in various degree, except ACEA and ACBU low dose group, and the increased SOD level that other each group can be in various degree.As seen, ACPE, ACEA and ACBU all can be by the content of MDA in the reduction serum in various degree, the increased SOD level, and the anti-oxidation function of enhancing diabetic mice body, the protection body is avoided the further injury of free radical.
Claims (8)
1. a Fructus actinidiae chinensis extract is characterized in that: extract acquisition by following methods: get fresh belt leather Fructus actinidiae chinensis, with its chopping, with methanol heating and refluxing extraction twice, be followed successively by 1.5-2.5h, 0.5-1.5h; Extracted twice liquid is merged, filters, concentrate to get Fructus actinidiae chinensis methanol total extract; Fructus actinidiae chinensis methanol total extract is used petroleum ether, ethyl acetate, n-butanol extraction successively, decompress filter, concentrated Fructus actinidiae chinensis Petroleum ether extraction position, ethyl acetate extraction position and the n-butanol extraction position of obtaining respectively.
2. Fructus actinidiae chinensis extract according to claim 1 is characterized in that: described extract be Fructus actinidiae chinensis ligroin extraction, ethyl acetate extraction or n-butanol extract in a kind of or its combination in any.
3. the extracting method of a Fructus actinidiae chinensis extract is characterized in that: the method that may further comprise the steps: get fresh belt leather Fructus actinidiae chinensis, with its chopping, with methanol heating and refluxing extraction twice, be followed successively by 1.5-2.5h, 0.5-1.5h; Extracted twice liquid is merged, filters, concentrate to get Fructus actinidiae chinensis methanol total extract; Fructus actinidiae chinensis methanol total extract is used petroleum ether, ethyl acetate, n-butanol extraction successively, decompress filter, concentrated Fructus actinidiae chinensis Petroleum ether extraction position, ethyl acetate extraction position and the n-butanol extraction position of obtaining respectively.
4. the extracting method of Fructus actinidiae chinensis extract according to claim 3, it is characterized in that: described heating-up temperature is 60-80 ℃.
5. the application of Fructus actinidiae chinensis extract as claimed in claim 1 aspect blood sugar lowering.
6. the application of Fructus actinidiae chinensis extract as claimed in claim 1 aspect the preparation hypoglycemic drug.
7. the application of Fructus actinidiae chinensis extract as claimed in claim 1 aspect the preparation alpha-glucosidase inhibitor medicine.
8. alpha-glucosidase inhibitor medicine application aspect the blood sugar lowering in the glycosuria sick body of a Fructus actinidiae chinensis extract preparation as claimed in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103853628A CN102861114A (en) | 2012-10-08 | 2012-10-08 | Kiwi fruit extract and extraction method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103853628A CN102861114A (en) | 2012-10-08 | 2012-10-08 | Kiwi fruit extract and extraction method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102861114A true CN102861114A (en) | 2013-01-09 |
Family
ID=47440431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012103853628A Pending CN102861114A (en) | 2012-10-08 | 2012-10-08 | Kiwi fruit extract and extraction method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861114A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107173812A (en) * | 2017-07-14 | 2017-09-19 | 贵州省苑博生态农业开发有限公司 | A kind of Kiwi fruit health product and preparation method thereof |
| CN110200088A (en) * | 2019-07-05 | 2019-09-06 | 中资国业牡丹产业集团有限公司 | A kind of peony seeds balanced type ready-mixed oil and preparation method thereof |
| CN113583080A (en) * | 2021-08-13 | 2021-11-02 | 中南大学 | Compound and preparation method and application thereof |
| CN115997793A (en) * | 2023-02-13 | 2023-04-25 | 贵州大学 | Kiwi fruit extract, preparation method and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006016728A1 (en) * | 2004-08-10 | 2006-02-16 | Helixir Co., Ltd. | Composition comprising the extract of actinidia arguta for preventing and treating baldness disorders and seborrheic skin disorders |
-
2012
- 2012-10-08 CN CN2012103853628A patent/CN102861114A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006016728A1 (en) * | 2004-08-10 | 2006-02-16 | Helixir Co., Ltd. | Composition comprising the extract of actinidia arguta for preventing and treating baldness disorders and seborrheic skin disorders |
Non-Patent Citations (2)
| Title |
|---|
| 徐一新等: "猕猴桃属植物化学成分和生物活性研究进展", 《解放军药学学报》 * |
| 王昌钊: "葛枣猕猴桃果实化学成分及生物活性研究", 《中国优秀硕士学位论文全文数据库》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107173812A (en) * | 2017-07-14 | 2017-09-19 | 贵州省苑博生态农业开发有限公司 | A kind of Kiwi fruit health product and preparation method thereof |
| CN110200088A (en) * | 2019-07-05 | 2019-09-06 | 中资国业牡丹产业集团有限公司 | A kind of peony seeds balanced type ready-mixed oil and preparation method thereof |
| CN113583080A (en) * | 2021-08-13 | 2021-11-02 | 中南大学 | Compound and preparation method and application thereof |
| CN113583080B (en) * | 2021-08-13 | 2022-09-30 | 中南大学 | Compound and preparation method and application thereof |
| CN115997793A (en) * | 2023-02-13 | 2023-04-25 | 贵州大学 | Kiwi fruit extract, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kumar et al. | Antidiabetic activity of methanolic bark extract of Albizia odoratissima Benth. in alloxan induced diabetic albino mice | |
| Aja et al. | Evaluation of anti-diabetic effect and liver enzymes activity of ethanol extract of Pterocarpus santalinoides in alloxan induced diabetic albino rats | |
| Widjaja et al. | Glucose lowering effect of basil leaves in diabetic rats | |
| Mostafa et al. | Anti-inflammatory, antinociceptive and antipyretic properties of the aqueous extract of Clematis brachiata leaf in male rats | |
| Li et al. | The anti-hyperglycemic effect of plants in genus Gynura Cass. | |
| CN104491350A (en) | Health product capable of regulating health of heart and cerebral vessels and reducing risk of cardiovascular and cerebrovascular diseases | |
| Ramappa et al. | Mulberry 1-deoxynojirimycin (DNJ): an exemplary compound for therapeutics | |
| CN102861114A (en) | Kiwi fruit extract and extraction method and application thereof | |
| TW201725046A (en) | Uses of Cistanche tubulosa extract and isoacteoside in protecting muscles | |
| Ardiana et al. | Antidiabetic activity studies of white tea (Camellia sinensis (L.) O. Kuntze) ethanolic extracts in streptozotocin-nicotinamide induced diabetic rats | |
| CN103536615A (en) | Preparation method of didymin and isosakuranetin, and application thereof in anti-diabetic medicine | |
| CN104523742A (en) | Polysaccharide composition with effects of protecting livers and improving immunity and application of polysaccharide composition | |
| CN103860611A (en) | Crape myrtle extract as well as extraction method and application thereof | |
| CN102151281B (en) | Flavonoid compound for preventing and treating diabetes and medicament application thereof | |
| CN102078356B (en) | Preparation method and applications of sugar-reducing effective part of chicory | |
| CN106038700A (en) | Application of butterflybush flower and extract in preparation of medicine for treating pulmonary heart disease | |
| CN103550281B (en) | The pharmaceutical composition of a kind of prevention and therapy diabetes and complication thereof and preparation thereof | |
| Okokon et al. | Antiplasmodial and antidiabetic activities of ethanolic leaf extract of Heinsia crinata | |
| CN102068475B (en) | Application and blood-sugar lowering effective part of trapa acornis nakano shell as well as extraction method of blood-sugar lowering effective part | |
| CN101156908B (en) | Application of argentina anserina extractive in preparation of alpha glycosidase enzymes inhibitors | |
| CN1985917B (en) | Medicine composition for reducing blood sugar, reducing blood fat and controlling diabetes complication | |
| CN103893306B (en) | A kind of blackberry seed effective ingredient and extracting method thereof, application | |
| CN105012826A (en) | Alpinia oxyphylla leaf extract and preparation method and application thereof | |
| CN104906190A (en) | Antler powder wine and preparation method thereof | |
| CN103083429A (en) | Blood fat-reducing traditional Chinese medicine formula |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130109 |